MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity

被引:42
作者
Santoro, Raffaela [1 ]
Zanotto, Marco [1 ]
Carbone, Carmine [1 ]
Piro, Geny [1 ,2 ]
Tortora, Giampaolo [2 ,3 ]
Melisi, Davide [1 ,3 ]
机构
[1] Univ Verona, Dept Med, Digest Mol Clin Oncol Res Unit, Verona, Italy
[2] Univ Verona, Dept Med, Lab Oncol & Mol Therapy, Verona, Italy
[3] Azienda Osped Univ Integrata, Med Oncol Unit, Verona, Italy
关键词
MEKK3; YAP; TAZ; pancreatic cancer; NF-KAPPA-B; ANTI-VEGF TREATMENT; ACTIVATION; RESISTANCE; THERAPY; EXPRESSION; PATHWAYS; RECEPTOR; SURVIVAL; TARGET;
D O I
10.21873/anticanres.12431
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Pancreatic cancer is one of the most threatening and poorly understood human malignancies. MEKK3 (MAP3K3) is a serine/threonine kinase activated by different signaling pathways. YAP and TAZ are critical oncogenic effectors in pancreatic cancer. We hypothesized that MEKK3 could sustain pancreatic cancer by inducing YAP/TAZ oncogenic activities. Materials and Methods: In Panc1 and AsPC1 pancreatic cancer cell lines MEKK3 was knocked-out (KO) by the CRISPR/Cas9 method. These cells were used to evaluate MEKK3 contribution to the expression of YAP/TAZ and their target genes, cell migration, stemness, and in vivo tumor growth. Results: MEKK3 KO reduced both EMT and cell migration, the size of 3D colonies and the percentage of CD44(+)/CD24(+)/EpCAM(+) CSC, promoter recruitment of YAP/TAZ and the expression of their target genes. It reduced tumor growth and prolonged mice overall survival. Conclusion: Silencing of MEKK3 represents a valid approach to revert in vivo the aggressiveness of pancreatic cancer by modulating YAP/TAZ transcriptional activities.
引用
收藏
页码:1937 / 1946
页数:10
相关论文
共 42 条
  • [1] MAP kinase pathways: The first twenty years
    Avruch, Joseph
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2007, 1773 (08): : 1150 - 1160
  • [2] Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling
    Carbone, C.
    Piro, G.
    Gaianigo, N.
    Ligorio, F.
    Santoro, R.
    Merz, V.
    Simionato, F.
    Zecchetto, C.
    Falco, G.
    Conti, G.
    Kamga, P. T.
    Krampera, M.
    Di Nicolantonio, F.
    De Franceschi, L.
    Scarpa, A.
    Tortora, G.
    Melisi, D.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2018, 42 (03) : 334 - 343
  • [3] Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
    Carbone, Carmine
    Piro, Geny
    Simionato, Francesca
    Ligorio, Francesca
    Cremolini, Chiara
    Loupakis, Fotios
    Ali, Greta
    Rossini, Daniele
    Merz, Valeria
    Santoro, Raffaela
    Zecchetto, Camilla
    Zanotto, Marco
    Di Nicolantonio, Federica
    Bardelli, Alberto
    Fontanini, Gabriella
    Tortora, Giampaolo
    Melisi, Davide
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4312 - 4322
  • [4] Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment
    Carbone, Carmine
    Tamburrino, Anna
    Piro, Geny
    Boschi, Federico
    Cataldo, Ivana
    Zanotto, Marco
    Mina, Maria M.
    Zanini, Silvia
    Sbarbati, Andrea
    Scarpa, Aldo
    Tortora, Giampaolo
    Melisi, Davide
    [J]. ANTI-CANCER DRUGS, 2016, 27 (01) : 29 - 40
  • [5] An Angiopoietin-like Protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis
    Carbone, Carmine
    Piro, Geny
    Fassan, Matteo
    Tamburrino, Anna
    Mina, Maria Mihaela
    Zanotto, Marco
    Chiao, Paul J.
    Bassi, Claudio
    Scarpa, Aldo
    Tortora, Giampaolo
    Melisi, Davide
    [J]. ONCOTARGET, 2015, 6 (15) : 13822 - 13834
  • [6] NF-κB as a target for pancreatic cancer therapy
    Carbone, Carmine
    Melisi, Davide
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 : S1 - S10
  • [7] Anti-VEGF Treatment-Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype
    Carbone, Carmine
    Moccia, Tania
    Zhu, Cihui
    Paradiso, Genni
    Budillon, Alfredo
    Chiao, Paul J.
    Abbruzzese, James L.
    Melisi, Davide
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (17) : 5822 - 5832
  • [8] Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells
    Fan, Yihui
    Ge, Ningling
    Wang, Xiaosong
    Sun, Wenjing
    Mao, Renfang
    Bu, Wen
    Creighton, Chad J.
    Zheng, Pingju
    Vasudevan, Sanjeev
    An, Lei
    Yang, Jinshu
    Zhao, Yi-Jue
    Zhang, Huiyuan
    Li, Xiao-Nan
    Rao, Pulivarthi H.
    Leung, Eastwood
    Lu, Yong-Jie
    Gray, Joe W.
    Schiff, Rachel
    Hilsenbeck, Susan G.
    Osborne, C. Kent
    Yang, Jianhua
    Zhang, Hong
    [J]. JOURNAL OF PATHOLOGY, 2014, 232 (01) : 75 - 86
  • [9] EMT and Treatment Resistance in Pancreatic Cancer
    Gaianigo, Nicola
    Melisi, Davide
    Carbone, Carmine
    [J]. CANCERS, 2017, 9 (09)
  • [10] Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis
    Hasan, Raghibul
    Sharma, Rinu
    Saraya, Anoop
    Chattopadhyay, Tushar K.
    DattaGupta, Siddartha
    Walfish, Paul G.
    Chauhan, Shyam S.
    Ralhan, Ranju
    [J]. BMC CANCER, 2014, 14